Abstract
According to a recent World Health Organization survey, there are over four hundred million people worldwide suffering from mental and neurological disorders schizophrenia affects some forty-five million people, and unipolar major depression ranked fifth in major causes of disability and death. Clearly it is of the utmost importance to develop new, effective, and safe neuro-pharmaceuticals with this increasing global burden of disease. To this end, we have developed a strategy of generating monoclonal antibodies that act as modulators of the cell-surface central nervous system receptor-ion channel complexes. In this review we will focus on the generation and characterization of a monoclonal antibody that acts as a partial agonist to the N-methyl-D-aspartate receptor. The creation of peptide mimetics, derived from this monoclonal antibody, that may be useful as cognitive enhancers and protect neurons hypoxic and ischemic insults caused by stroke, will also be discussed.
Keywords: methyl-D-Aspartate Receptors, anticonvulsant MK-801, Monoclonal Antibody Production, Primary Hippocampal Cultures, TCP Binding Assays, B6B21, Peptide Synthesis
Current Drug Targets
Title: The Use of Antibody Engineering to Create Novel Drugs that Target N-methyl-D-Aspartate Receptors
Volume: 2 Issue: 3
Author(s): Joseph R. Moskal, Hirotaka Yamamoto and Patricia A. Colley
Affiliation:
Keywords: methyl-D-Aspartate Receptors, anticonvulsant MK-801, Monoclonal Antibody Production, Primary Hippocampal Cultures, TCP Binding Assays, B6B21, Peptide Synthesis
Abstract: According to a recent World Health Organization survey, there are over four hundred million people worldwide suffering from mental and neurological disorders schizophrenia affects some forty-five million people, and unipolar major depression ranked fifth in major causes of disability and death. Clearly it is of the utmost importance to develop new, effective, and safe neuro-pharmaceuticals with this increasing global burden of disease. To this end, we have developed a strategy of generating monoclonal antibodies that act as modulators of the cell-surface central nervous system receptor-ion channel complexes. In this review we will focus on the generation and characterization of a monoclonal antibody that acts as a partial agonist to the N-methyl-D-aspartate receptor. The creation of peptide mimetics, derived from this monoclonal antibody, that may be useful as cognitive enhancers and protect neurons hypoxic and ischemic insults caused by stroke, will also be discussed.
Export Options
About this article
Cite this article as:
Moskal R. Joseph, Yamamoto Hirotaka and Colley A. Patricia, The Use of Antibody Engineering to Create Novel Drugs that Target N-methyl-D-Aspartate Receptors, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348399
DOI https://dx.doi.org/10.2174/1389450013348399 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure-Retention Relationship Study of HPLC Data of Antiepileptic Hydantoin Analogues
Current Computer-Aided Drug Design Synthesis and Biological Evaluation of Novel 2,3-disubstituted Benzofuran Analogues of GABA as Neurotropic Agents
Medicinal Chemistry Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine The Four Human γ-Aminobutyric Acid (GABA) Transporters: Pharmacological Characterization and Validation of a Highly Efficient Screening Assay
Combinatorial Chemistry & High Throughput Screening Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy New Insights into Pre-, Intra- and Post-Operative Brain Mapping in Low- Grade Glioma Surgery: Towards a Longitudinal Study of Cerebral Plasticity
Current Medical Imaging Current Methods in the Automatic Tissue Segmentation of 3D Magnetic Resonance Brain Images
Current Medical Imaging Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
Medicinal Chemistry Ultrasound-Induced Blood-Brain Barrier Opening
Current Pharmaceutical Biotechnology Editorial [Hot Topic: PET and SPECT in Drug Evaluation and Drug Design Imaging Inflammatory Processes, Tumors, and the Endocannabinoid System(Executive Editor: Aren van Waarde)]
Current Pharmaceutical Design Pharmacotherapy of Obesity - Benefit, Bias and Hyperbole
Current Medicinal Chemistry Implementation of Bagged SVM Ensemble Model for Classification of Epileptic States Using EEG
Current Pharmaceutical Biotechnology Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews The Interleukin-1 System: An Attractive and Viable Therapeutic Target in Neurodegenerative Disease
Current Drug Targets - CNS & Neurological Disorders Antiepileptic Drug-Induced Hypersensitivity Syndrome Reactions
Current Drug Safety Activation of Kir2.3 Channels by Tenidap Suppresses Epileptiform Burst Discharges in Cultured Hippocampal Neurons
CNS & Neurological Disorders - Drug Targets Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Synthesis and Anticonvulsant Activity of Some Cinnamylpiperazine Derivatives
Letters in Drug Design & Discovery Molecular Docking Study, Green Synthesis and Pharmacological Evaluation of 1,3,4-thiadiazole Derivatives as Potential Antiepileptic Agents
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Neurogenesis for Prevention and Recovery from Alzheimers Disease: Allopregnanolone as a Proof of Concept Neurogenic Agent
Current Alzheimer Research